Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes Patients

被引：5
|
作者：
Thomas, Melissa K.
Nikooienejad, Amir
Bray, Ross
Cui, Xuewei
Wilson, Jonathan M.
Duffin, Kevin L.
Milicevic, Zvonko
Haupt, Axel
Robins, Deborah A.
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-980-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
980-P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to a Selective Long-Acting GLP-1 Receptor Agonist
    Urva, Shweta
    Nauck, Michael A.
    Coskun, Tamer
    Cui, Xuewei
    Haupt, Axel
    Benson, Charles
    Loghin, Corina
    [J]. DIABETES, 2019, 68
  • [42] The novel dual GIP and GLP-1 receptor agonist, tirzepatide, transiently delays gastric emptying similarly to a selective long-acting GLP-1 receptor agonist
    Urva, S.
    Nauck, M. A.
    Coskun, T.
    Cui, X.
    Haupt, A.
    Benson, C. T.
    Loghin, C.
    [J]. DIABETOLOGIA, 2019, 62 : S58 - S58
  • [43] Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis
    Stefanou, Maria-Ioanna
    Theodorou, Aikaterini
    Malhotra, Konark
    Aguiar de Sousa, Diana
    Katan, Mira
    Palaiodimou, Lina
    Katsanos, Aristeidis H.
    Koutroulou, Ioanna
    Lambadiari, Vaia
    Lemmens, Robin
    Giannopoulos, Sotirios
    Alexandrov, Andrei, V
    Siasos, Gerasimos
    Tsivgoulis, Georgios
    [J]. EUROPEAN STROKE JOURNAL, 2024, 9 (03) : 530 - 539
  • [44] Efficacy and safety of once weekly tirzepatide, a dual GIP/GLP-1 receptor agonist versus placebo as monotherapy in people with type 2 diabetes (SURPASS-1)
    Rosenstock, J.
    Wysham, C.
    Frias, J. P.
    Kaneko, S.
    Lee, C. J.
    Lando, L. Fernandez
    Mao, H.
    Cui, X.
    Thieu, V. T.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 246 - 246
  • [45] Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes
    Pirro, Valentina
    Roth, Kenneth D.
    Lin, Yanzhu
    Willency, Jill A.
    Milligan, Paul L.
    Wilson, Jonathan M.
    Ruotolo, Giacomo
    Haupt, Axel
    Newgard, Christopher B.
    Duffin, Kevin L.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (02): : 363 - 378
  • [46] Tirzepatide: NICE recommends another GLP-1 agonist for type 2 diabetes
    Mahase, Elisabeth
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2023, 382 : 2074
  • [47] Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
    Michael A. Nauck
    David A. D‘Alessio
    [J]. Cardiovascular Diabetology, 21
  • [48] Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
    Nauck, Michael A.
    D'Alessio, David A.
    [J]. CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [49] Effect of tirzepatide, a dual GIP and GLP-1 receptor agonist, on glycemic control and body weight in Japanese patients with T2DM
    Ohwaki, Kenji
    Furihata, Kenichi
    Mimura, Hanaka
    Oura, Tomonori
    Imaoka, Takeshi
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35
  • [50] Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
    Rosenstock, Julio
    Wysham, Carol
    Frias, Juan P.
    Kaneko, Shizuka
    Lee, Clare J.
    Lando, Laura Fernandez
    Mao, Huzhang
    Cui, Xuewei
    Karanikas, Chrisanthi A.
    Thieu, Vivian T.
    [J]. LANCET, 2021, 398 (10295): : 143 - 155
12345